Gilead share price

Key events shows relevant news articles on days with large price movements.

Morgan Stanley initiates coverage on Arcellx. Search markets. News The word News. My Watchlist. Business Insider logo The words "Business Insider". Close icon Two crossed lines that form an 'X'.

Gilead share price

Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share. Biktarvy's success creates a patent cliff in , and it could be difficult to improve on this daily HIV drug regimen. Morningstar brands and products. Investing Ideas. As of Mar 8, pm Delayed Price Closed. Unlock our analysis with Morningstar Investor. Start Free Trial. Mar 8, Fair Value. Feb 3,

In the s, Gilead received approval for drugs including Viread and Hepsera, among others. Price USD

UK drugmaker steps up investment in long-acting medication to protect those exposed to the virus. Companies have yet to provide investors with convincing post-pandemic strategies. Shares in Swiss pharma group rally after analyst discovers data on immunotherapy medicine on website. Boutique bank famed for its harmonious culture is dealing with a bitter lawsuit and the questions that come with success. Examples of innovative services and advice developed by legal teams in Asia-Pacific. Financial Times Close. Search the FT Search.

Key events shows relevant news articles on days with large price movements. Bristol-Myers Squibb Co. BMY 0. Amgen Inc. AMGN 0. CVS Health Corp. CVS 1. Bank of America Corp. BAC 0. JNJ 0.

Gilead share price

Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share. Biktarvy's success creates a patent cliff in , and it could be difficult to improve on this daily HIV drug regimen. Morningstar brands and products. Investing Ideas. As of Mar 8, pm Delayed Price Closed. Unlock our analysis with Morningstar Investor. Start Free Trial. Mar 8,

Cassiopeia win rate

Industry Drug Manufacturers - General. Start Free Trial. The company continued its growth in the s. Cash from financing. Gilead Sciences Inc. Actions Add to watchlist Add to portfolio Add an alert. TSLA 1. Cash from operations. Download Reset. Morningstar brands and products. BIIB 1. Biktarvy's success creates a patent cliff in , and it could be difficult to improve on this daily HIV drug regimen. Global Investors 4.

.

BAC 0. Represents the total incurred expenses through normal operations. Net cash used or generated in investing activities such as purchasing assets. Legal services. Return on assets. Net profit margin. Industry Drug Manufacturers - General. See how this stock stacks up to its competitors with Morningstar Investor. BIIB 1. Show More.